Evidence map›Paper›PMID 42562882›Full record

ArticleEMBO molecular medicine2026

Deep visual multi-omics profiling links morphology and molecular programs in clear cell renal cell carcinoma.

Hella A Bolck, Ede Migh, Andras Kriston, Natalia Zajac, Susanne Kreutzer, Tiberiu Totu, Peter Leary, Ferenc Kovacs, Dorothea Rutishauser, Sibylle Pfammatter and 8 more

Abstract read
In one paragraph

Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hella A BolckDepartment of Pathology and Molecular Pathology, University Hospital Zürich and University of Zürich, Zürich, Switzerland. Hella.Bolck@zhaw.ch.ORCID http://orcid.org/0000-0001-5157-0490
Ede MighSynthetic and Systems Biology Unit, Biological Research Centre, HUN-REN, Szeged, Hungary.
Andras KristonSingle-Cell Technologies Ltd., Szeged, Hungary.
Natalia ZajacFunctional Genomics Center Zürich, Eidgenössische Technische Hochschule Zürich/University of Zürich, Zürich, Switzerland.
Susanne KreutzerFunctional Genomics Center Zürich, Eidgenössische Technische Hochschule Zürich/University of Zürich, Zürich, Switzerland.
Tiberiu TotuSwiss Institute of Bioinformatics, Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-8268-1740
Peter LearyFunctional Genomics Center Zürich, Eidgenössische Technische Hochschule Zürich/University of Zürich, Zürich, Switzerland.ORCID http://orcid.org/0000-0003-1430-6185
Ferenc KovacsSingle-Cell Technologies Ltd., Szeged, Hungary.
Dorothea RutishauserDepartment of Pathology and Molecular Pathology, University Hospital Zürich and University of Zürich, Zürich, Switzerland.ORCID http://orcid.org/0000-0003-2303-103X
Sibylle PfammatterFunctional Genomics Center Zürich, Eidgenössische Technische Hochschule Zürich/University of Zürich, Zürich, Switzerland.
Jonas GrossmannFunctional Genomics Center Zürich, Eidgenössische Technische Hochschule Zürich/University of Zürich, Zürich, Switzerland.ORCID http://orcid.org/0000-0002-6899-9020
Harini LakshminarayananDepartment of Pathology and Molecular Pathology, University Hospital Zürich and University of Zürich, Zürich, Switzerland.ORCID http://orcid.org/0000-0002-0641-3266
Debleena BasuDepartment of Pathology and Molecular Pathology, University Hospital Zürich and University of Zürich, Zürich, Switzerland.
Cassandra LitchfieldDepartment of Pathology and Molecular Pathology, University Hospital Zürich and University of Zürich, Zürich, Switzerland.
Marija BuljanSwiss Institute of Bioinformatics, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-3615-6691
Niels J RuppDepartment of Pathology and Molecular Pathology, University Hospital Zürich and University of Zürich, Zürich, Switzerland.
Peter HorvathSynthetic and Systems Biology Unit, Biological Research Centre, HUN-REN, Szeged, Hungary. horvath.peter@brc.hu.ORCID http://orcid.org/0000-0002-4492-1798
Holger MochDepartment of Pathology and Molecular Pathology, University Hospital Zürich and University of Zürich, Zürich, Switzerland. holger.moch@usz.ch.ORCID http://orcid.org/0000-0002-7986-2839

Funding

Edoardo R., Giovanni, Guiseppe and Chiarina Sassella Foundation n/aJulius Müller Foundation n/a
6 · The paper itself

Abstract

Clear cell renal cell carcinoma exhibits striking intra-tumoral heterogeneity at morphological and genetic levels, complicating treatment and contributing to disease progression. CcRCCs with rhabdoid differentiation are highly aggressive tumors characterized by distinct histopathologies. However, the relationship between morphology, underlying molecular alterations, and tumor behavior remains largely unclear. Here, we present Deep Visual Multi-Omics, an approach integrating digital pathology, morphology-guided single-cell isolation, and ultra-sensitive multi-omics profiling to link cell morphologies to their molecular underpinnings. Across five tumors, we profiled ~40,000 AI-classified and expert-curated cells. We identified progressive molecular dysregulation across cells with increasing histopathological grade coexisting within heterogeneous tumors as well as distinct molecular alterations associated with aggressive rhabdoid ccRCC cells, including signatures consistent with enhanced FOXM1-driven proliferation, altered cell-matrix interactions, and a putative immunomodulatory phenotype. Notably, rhabdoid cells exhibited elevated expression of IFN-beta, PD-L1, CD38, ITGB2, and integrin signaling, suggesting that they themselves may act as a source of signals influencing the local immune microenvironment. Besides providing new insights into the biology of ccRCC and highlighting avenues for future translational studies, this illustrates the potential of Deep Visual Multi-omics to dissect cancer heterogeneity and characterize high-risk cell populations.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsGene Expression ProfilingHumansMultiomics

Identifiers

PMID42562882
PMCPMC13562643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.